Safety issues related to retroviral-mediated gene transfer in humans

Kenneth Cornetta, Richard A. Morgan, W. French Anderson

Research output: Contribution to journalReview article

186 Scopus citations

Abstract

The first three approved human clinical trials utilizing retroviral-mediated gene transfer are now underway. While this technology holds great promise for the study and treatment of human disease, it also poses a number of safety concerns. In evaluating clinical protocols, potential complications and the likelihood of their occurrence are estimated by review committees so that a risk/benefit assessment can be made. Current knowledge, reviewed in this article, suggests that no acute complications secondary to retroviral-mediated gene transfer are likely, but the possibility of long-term or unforeseen sequelae in patients suggests the need for post-treatment monitoring.

Original languageEnglish (US)
Pages (from-to)5-14
Number of pages10
JournalHuman Gene Therapy
Volume2
Issue number1
DOIs
StatePublished - Jan 1 1991

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this